Monocyte-derived cells invade brain parenchyma and amyloid plaques in human Alzheimer's disease hippocampus

Clara Muñoz-Castro1,2,3, Marina Mejias-Ortega4,3, Elisabeth Sanchez-Mejias4,3

  • 1Dpto. Bioquimica Y Biologia Molecular, Facultad de Farmacia, Universidad de Sevilla, C/ Prof. Garcia Gonzalez 2, 41012, Seville, Spain.

Insights

Monocyte-derived cells invade the brain in advanced Alzheimer's disease (AD), infiltrating amyloid plaques and potentially contributing to disease severity. This suggests new therapeutic targets beyond microglia for AD treatment.

Area of Science:

  • Neuroimmunology
  • Alzheimer's Disease Pathogenesis
  • Innate Immune Response in CNS

Background:

  • Microglia are key players in CNS innate immunity and Alzheimer's disease (AD) pathogenesis.
  • The role of nonparenchymal or brain-infiltrated myeloid cells in AD progression is not well understood.

Purpose of the Study:

  • To investigate the infiltration and role of monocyte-derived cells (MDC) in the brain parenchyma during advanced stages of Alzheimer's disease.

Main Methods:

  • Transcriptional analysis of post-mortem human hippocampus.
  • Immunohistochemical characterization.
  • Analysis of gene expression, including Cd163, in relation to microglial and monocyte markers.

Main Results:

  • Monocyte-derived cells (MDC) invade hippocampal parenchyma in advanced AD (Braak V-VI stages).
  • Infiltrating MDC express monocyte-associated genes like Cd163 and adopt a microglial-like morphology near blood vessels.
  • These MDC infiltrate amyloid plaques, contributing to myeloid cell heterogeneity, and are associated with endothelial activation and potential blood-brain barrier damage.

Conclusions:

  • Monocyte infiltration into the brain parenchyma occurs in advanced AD, particularly in individuals with microglial dysfunction.
  • This infiltration is linked to endothelial activation and may represent a consequence, rather than a cause, of severe AD pathology.
  • Findings suggest peripheral immune cells as potential therapeutic targets for modulating AD amyloid pathology.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...